Compare Vanguard Mega Cap Growth ETF (MGK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs BIO-TECHNE Corp — how do they compare? Vanguard Mega Cap Growth ETF trades at $87.68, while BIO-TECHNE Corp trades at $71.69 (market cap $11.16B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Vanguard Mega Cap Growth ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Vanguard Mega Cap Growth ETF nearer its low. Which is the better fit depends on your goals.
| MGK | TECH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $92.06 | $72.12 |
52-Week Low | $70.70 | $43.31 |
Market Cap | — | $11.16B |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Mega Cap Growth ETF, trades at $86.83 with no recent price change. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights its low expense ratio of 0.05% and concentrated portfolio of 69 large-cap growth stocks, including heavy exposure to technology leaders. A 1:5 stock split occurred on April 21, 2026, and a small dividend is scheduled for June 2026.
MGK offers exposure to top U.S. growth companies but faces risks from high concentration in tech stocks and market volatility. Its long-term performance history and cost efficiency present opportunities for growth-focused investors, though sector-specific downturns could impact returns significantly.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
